[go: up one dir, main page]

AU2003209285A1 - Deazapurine nucleoside analogs and their use as therapeutic agents - Google Patents

Deazapurine nucleoside analogs and their use as therapeutic agents

Info

Publication number
AU2003209285A1
AU2003209285A1 AU2003209285A AU2003209285A AU2003209285A1 AU 2003209285 A1 AU2003209285 A1 AU 2003209285A1 AU 2003209285 A AU2003209285 A AU 2003209285A AU 2003209285 A AU2003209285 A AU 2003209285A AU 2003209285 A1 AU2003209285 A1 AU 2003209285A1
Authority
AU
Australia
Prior art keywords
therapeutic agents
nucleoside analogs
deazapurine nucleoside
deazapurine
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003209285A
Inventor
Haoyun An
Varaprasad Chamakura
Yili Ding
Zhi Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Research and Development
Original Assignee
Ribapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribapharm Inc filed Critical Ribapharm Inc
Publication of AU2003209285A1 publication Critical patent/AU2003209285A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044Pyrrole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003209285A 2002-01-17 2003-01-17 Deazapurine nucleoside analogs and their use as therapeutic agents Abandoned AU2003209285A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35029602P 2002-01-17 2002-01-17
US60/350,296 2002-01-17
PCT/US2003/001545 WO2003061576A2 (en) 2002-01-17 2003-01-17 Deazapurine nucleoside analogs and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
AU2003209285A1 true AU2003209285A1 (en) 2003-09-02

Family

ID=27613377

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003209285A Abandoned AU2003209285A1 (en) 2002-01-17 2003-01-17 Deazapurine nucleoside analogs and their use as therapeutic agents

Country Status (2)

Country Link
AU (1) AU2003209285A1 (en)
WO (3) WO2003062256A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094770B2 (en) 2000-04-13 2006-08-22 Pharmasset, Ltd. 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (en) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Use of nucleoside derivatives for preparation of pharmaceutical compositions for treating infections caused by flaviviruses and pestiviruses
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN101172993A (en) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AU2003256619A1 (en) 2002-07-24 2004-02-09 Isis Pharmaceuticals, Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
IL166640A0 (en) 2002-08-01 2006-01-15 Pharmasset Ltd Compounds with the bicyclo Ä4.2.1Ü nonane system for the treatment of flaviviridae infections
EA200500584A1 (en) * 2002-09-30 2006-02-24 Дженелэбс Текнолоджиз, Инк. NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY THE HEPATITIS C VIRUS
US7094768B2 (en) 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
ES2624353T3 (en) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Methyl nucleosides in combination with interferon and Flaviviridae mutation
RU2005121904A (en) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) METHOD FOR PRODUCING 2`-BRANCHED NUCLEOSIDES
WO2004065398A2 (en) * 2003-01-15 2004-08-05 Ribapharm Inc. Synthesis and use of 2'-substituted-n6-modified nucleosides
EP4032897B1 (en) 2003-05-30 2025-01-29 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
ATE478886T1 (en) * 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc PURINE NUCLEOSIDES FOR THE TREATMENT OF DISEASES CAUSED BY FLAVIVIDRAE, INCLUDING HEPATITIS C
US7151089B2 (en) 2003-10-27 2006-12-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
EP1687321A1 (en) * 2003-10-27 2006-08-09 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7157434B2 (en) * 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2005044835A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
IN2012DN04853A (en) 2004-02-20 2015-09-25 Boehringer Ingelheim Int
AR049384A1 (en) 2004-05-24 2006-07-26 Glaxo Group Ltd PURINA DERIVATIVES
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7414031B2 (en) 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
WO2007084157A2 (en) * 2005-03-23 2007-07-26 Genelabs Technologies, Inc. Nucleoside prodrugs for treating viral infections
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20090118220A1 (en) * 2006-04-03 2009-05-07 Astrazeneca Ab Substituted adenines and the uses thereof
WO2008005542A2 (en) * 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2028182A1 (en) * 2007-08-21 2009-02-25 Glaxo Group Limited Cysteine protease inhibitors
WO2008117046A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolo [4, 3-d] pyrimidines as antibacterial compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
WO2010027935A1 (en) 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP2013527145A (en) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー Stereoselective synthesis of phosphorus-containing activators
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201305185A (en) * 2010-09-13 2013-02-01 Gilead Sciences Inc 2'-fluoro substituted carbon-nucleoside analog for antiviral therapy
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
PT3042910T (en) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-spiro-nucleosides for use in the therapy of hepatitis c
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
AU2012358803C1 (en) 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013138236A1 (en) 2012-03-13 2013-09-19 Gilead Sciences , Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
HK1206362A1 (en) 2012-03-21 2016-01-08 Alios Biopharma, Inc. Solid form of thiophosphoramidate nucleotide prodrug
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2890704B1 (en) 2012-08-31 2018-02-28 Novartis AG 2'-ethynyl nucleoside derivatives for treatment of viral infections
KR20200060782A (en) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 Combination formulation of two antiviral compounds
CN105705511A (en) 2013-04-12 2016-06-22 艾其林医药公司 Deuterated nucleoside prodrugs useful for treating HCV
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3055319A4 (en) 2013-10-11 2018-01-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
BR112018002399A2 (en) 2015-08-06 2018-09-25 Chimerix, Inc. pyrrolopyrimidine nucleosides and analogs thereof, useful as antiviral agents
WO2017053216A2 (en) 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
PL3512863T3 (en) 2016-09-07 2022-04-04 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL295609B2 (en) 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EP3684771B1 (en) 2017-09-21 2024-11-27 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN112351799A (en) 2018-04-10 2021-02-09 阿堤亚制药公司 Treatment of HCV infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
BR112023026356A2 (en) 2021-06-17 2024-03-05 Atea Pharmaceuticals Inc METHOD FOR TREATING HEPATITIS C VIRUS OR A CONDITION RESULTING FROM A HEPATITIS C INFECTION, COMBINATION, USE OF THE COMBINATION, PHARMACEUTICAL COMPOSITION, AND, KIT FOR TREATMENT OF HEPATITIS C VIRUS
CZ2024224A3 (en) 2024-05-30 2025-12-10 Ústav organické chemie a biochemie AV ČR, v. v. i. 1H-pyrazolo[3,4-d]pyrimidine ribonucleosides with anti-tumour activity for the therapeutic use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134793A (en) * 1992-06-22 1993-12-23 Eli Lilly And Company 2'-deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (en) * 2000-05-26 2009-12-02 Idenix (Cayman) Limited Use of nucleoside derivatives for preparation of pharmaceutical compositions for treating infections caused by flaviviruses and pestiviruses
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR101005299B1 (en) * 2000-10-18 2011-01-04 파마셋 인코포레이티드 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
HUP0400726A3 (en) * 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase

Also Published As

Publication number Publication date
WO2003062256A1 (en) 2003-07-31
WO2003062257A1 (en) 2003-07-31
WO2003061576A3 (en) 2004-04-01
WO2003061576A2 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
AU2003209285A1 (en) Deazapurine nucleoside analogs and their use as therapeutic agents
AU2003225705A1 (en) Cytidine analogs and methods of use
IL173395A0 (en) Pyridazine derivatives and their use as therapeutic agents
GB0206876D0 (en) Therapeutic agents
GB0209991D0 (en) Therapeutic agents
GB0209995D0 (en) Therapeutic agents
GB0209997D0 (en) Therapeutic agents
AU2003261251A1 (en) Methods of delivering therapeutic agents
GB0210127D0 (en) Therapeutic agents
GB0210124D0 (en) Therapeutic agents
EP1478276A4 (en) Novel targeted compositions for diagnostic and therapeutic use
EP1487411A4 (en) Inhalable sustained therapeutic formulations
IL164463A0 (en) Use of osteoprotegerin in the preparation of medicaments
AU2003279911A8 (en) Therapeutic formulations
GB2392618B (en) Compositions for therapeutic use
GB0219660D0 (en) Therapeutic use
GB2409459B (en) Lightweight joint treatment formulation
GB0207410D0 (en) Compounds and their therapeutic use
PL397022A1 (en) Therapeutic agent
AU2003273803A1 (en) Use of triptans as antiviral agents
IL165934A0 (en) Novel adenosine analogues and their use as pharmaceutical agents
AU2003207605A1 (en) Deazapurine nucleoside analogs and their use as therapeutic agents
GB0208394D0 (en) Therapeutic agents
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
AU2003213349A1 (en) Therapeutic agent for pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase